A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease

Thorax

Volumn 55, Issue 4, 2000, Pages 289-294

  Van Noord, J A ^a   Bantje, Th A ^b   Eland, M E ^c   Korducki, L ^d,e   Cornelissen, P J G ^d,e  

^a Sittard Geleen Heerlen   (Netherlands)

^b Ignatius Hospital   (Netherlands)

^c Merwede Ziekenhuis   (Netherlands)

^d BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^e NONE

Author keywords

Anticholinergic agents; Chronic obstructive pulmonary disease; Ipratropium; Tiotropium

Indexed keywords

IPRATROPIUM BROMIDE; PLACEBO; SALBUTAMOL; SPIRIVAR; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; PARALLEL DESIGN; PEAK EXPIRATORY FLOW; POWDER INHALER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VITAL CAPACITY; XEROSTOMIA;

AGED; CHOLINERGIC ANTAGONISTS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; IPRATROPIUM; LUNG DISEASES, OBSTRUCTIVE; MALE; MIDDLE AGED; PEAK EXPIRATORY FLOW RATE; SCOPOLAMINE DERIVATIVES;

EID: 0034055236     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thorax.55.4.289     Document Type: Article

References (22)

1. 1 Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD): ERS consensus statement. Eur Respir J 1995;8:1398-420.
2. 2 Hay JG, Stone P, Carter J, et al. Bronchodilator reversibility, exercise performance and breathlessness in stable chronic obstructive pulmonary disease. Eur Respir J 1992;5:659-64.
3. 3 Gross NJ, Skorodin MS. Anticholinergic, antimuscarinic bronchodilators. Am Rev Respir Dis 1984;129:856-70.
4. 4 ATS Statement. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152: S77-120.
5. 5 Gross NJ. Ipratropium bromide. N Engl J Med 1988;319:486-94.
6. 6 Barnes PJ. Muscarinic receptor subtypes in airways. Life Sci 1993;52:521-7.
7. 7 Disse B, Reichl R, Speck G, et al. Ba679 Br, a novel anticholinergic bronchodilator. Life Sci 1993;52:537-44.
8. 8 Takahaski T, Belvisi MG, Patel H, et al. Effect of BA679 Br, a novel long-acting anticholinergic agent, on cholinergic neurotransmission in guinea pig and human airways. Am J Respir Crit Care Med 1994;150:1640-5.
9. 9 Maesen FPV, Smeets JJ, Costongs MAL, et al. BA679 Br, a new long-acting antimuscarinic bronchodilator: a pilot dose-escalation study. Eur Respir J 1993;6:1031-6.
10. 10 Maesen FPV, Smeets JJ, Sledsens TJH, et al. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Eur Respir J 1995;8:1506-13.
11. 11 O'Connor BJ, Towse LJ, Barnes PJ. Prolonged effect of tiotropium bromide on metacholine-induced bronchoconstriction in asthma. Am J Respir Crit Care Med 1996;154:876-80.
12. 12 Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flow. Eur Respir J 1993;6(Suppl 16):5-40.
13. R dry powder inhalation system over a range of COPD severity. Am J Respir Crit Care Med 1999;159(Suppl):A524.
14. 14 American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis 1991;144:1202-18.
15. 15 Ingram RH, Wellman JJ, Mc Fadden ER, et al. Relative contribution of large and small airways to flow limitation in normal subjects before and after atropine and isoproterenol. J Clin Invest 1977;59:696-703.
16. 16 Barnes PJ, Basbaum CB, Nadel JA. Autoradiographic localization of autonomic receptors in airway smooth muscle. Marked differences between large and small airways. Am Rev Respir Dis 1983;127:758-62.
17. 17 Macklem PT. The physiology of small airways. Am J Respir Crit Care Med 1998;157:S181-3.
18. 18 Gibson GJ, Kelly CA. Relation between FEV, and peak expiratory flow in patients with chronic airflow obstruction. Thorax 1988;43:335-6.
19. 19 Mitchell DM, Gildeh P, Dimond AH, et al. Value of serial peak expiratory flow measurements in assessing treatment response in chronic airflow limitation. Thorax 1986;41:606-10.
20. 20 Rennard SL, Serby CW, Ghafouri M, et al. Extended therapy with ipratropium is associated with improved lung function in patients with COPD. A retrospective analysis of data from seven clinical trials. Chest 1996;110:62-70.
21. 21 Littner M, Auerbach D, Campbell S, et al. The bronchodilator effects of tiotropium in stable COPD. Am J Respir Crit Care Med 1997;155(Suppl):A282.
22. 22 Disse B, Rominger K, Serby CW, et al. The pharmacokinetic (PK) profile of tiotropium during long-term treatment in stable COPD. Am J Respir Crit Care Med 1999;159(Suppl):A524.